Literature DB >> 26770355

Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.

Yuee Wang1, Qingqi Fan1, Ting Wang1, Jia Wen1, Hong Wang2, Tiansong Zhang3.   

Abstract

AIM: to evaluate the performance and accuracy of Controlled attenuation parameter CAP for hepatic steatosis detection.
METHODS: PubMed, EBSCO, Elsevier Science, Ovid, and Wiley were selected to search studies until August 31, 2014. Quality Assessment of Diagnostic Accuracy Studies checklist was used to assess the quality of included studies. Heterogeneity was evaluated using Q test. Sensitivity, specificity, diagnostic odds ratio (DOR), and the area under curve (AUC) with its 95% confidence intervals (CIs) were calculated to evaluate the accuracy of CAP for assessment of hepatic steatosis stage (≥ S1, ≥ S2 and ≥ S3).
RESULTS: Totally 11 studies (13 cohorts) with high methodological qualities were identified. The summary point estimations with 95% CIs of sensitivity, specificity, AUC and DORs were 0.78 (0.71, 0.84), 0.79 (0.70, 0.86), 0.86 (0.82, 0.88), and 14 (7, 27) for ≥ S1; 0.82 (0.74, 0.88), 0.79 (0.73, 0.85), 0.88 (0.85, 0.90) and 18 (10, 30) for ≥ S2; 0.86 (0.82, 0.89), 0.89 (0.86, 0.92), 0.94 (0.91, 0.96) and 51 (35, 76) for ≥ S3. Significant heterogeneity was found among the studies in ≥ S1 and ≥ S3. Threshold effect was existed in ≥ S3, but not in ≥ S1 and ≥ S2. Publication bias was not existed in ≥ S1 and ≥ S2 except ≥ S3.
CONCLUSION: CAP provides good sensitivity and specificity for detection of ≥ S1, ≥ S2, and ≥ S3 steatosis. However, future studies with large samples are still necessary to confirm the clinical application.

Entities:  

Keywords:  Controlled attenuation parameter; diagnostic meta-analysis; hepatic steatosis

Year:  2015        PMID: 26770355      PMCID: PMC4694255     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.

Authors:  M Sasso; I Tengher-Barna; M Ziol; V Miette; C Fournier; L Sandrin; R Poupon; A-C Cardoso; P Marcellin; C Douvin; V de Ledinghen; J-C Trinchet; M Beaugrand
Journal:  J Viral Hepat       Date:  2011-10-13       Impact factor: 3.728

2.  Multi-detector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom.

Authors:  Bernard A Birnbaum; Nicole Hindman; Julie Lee; James S Babb
Journal:  Radiology       Date:  2007-01       Impact factor: 11.105

3.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

Authors:  Magali Sasso; Michel Beaugrand; Victor de Ledinghen; Catherine Douvin; Patrick Marcellin; Raoul Poupon; Laurent Sandrin; Véronique Miette
Journal:  Ultrasound Med Biol       Date:  2010-09-27       Impact factor: 2.998

4.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

5.  Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.

Authors:  Mireen Friedrich-Rust; Daniela Romen; Johannes Vermehren; Susanne Kriener; Dilek Sadet; Eva Herrmann; Stefan Zeuzem; Joerg Bojunga
Journal:  Eur J Radiol       Date:  2011-11-26       Impact factor: 3.528

Review 6.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

Review 7.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

Authors:  Nina F Schwenzer; Fabian Springer; Christina Schraml; Norbert Stefan; Jürgen Machann; Fritz Schick
Journal:  J Hepatol       Date:  2009-06-11       Impact factor: 25.083

8.  A comparison of computed tomography, ultrasound and scintigraphy in the diagnosis of alcoholic liver disease.

Authors:  D R Meek; P R Mills; H W Gray; J G Duncan; R I Russell; J H McKillop
Journal:  Br J Radiol       Date:  1984-01       Impact factor: 3.039

9.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

10.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.

Authors:  Giorgio Bedogni; Stefano Bellentani; Lucia Miglioli; Flora Masutti; Marilena Passalacqua; Anna Castiglione; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2006-11-02       Impact factor: 3.067

View more
  18 in total

Review 1.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.

Authors:  Jing-Houng Wang; Hsin-You Ou; Yi-Hao Yen; Chien-Hung Chen; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

Review 3.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

4.  Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter.

Authors:  Marco Silva; Pedro Costa Moreira; Armando Peixoto; Ana Luísa Santos; Susana Lopes; Regina Gonçalves; Pedro Pereira; Hélder Cardoso; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2018-04-20

5.  Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B.

Authors:  Alexander Hodge; Sarah Lim; Evan Goh; Ophelia Wong; Philip Marsh; Virginia Knight; William Sievert; Barbora de Courten
Journal:  Nutrients       Date:  2017-01-10       Impact factor: 5.717

6.  Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Authors:  Stevan A Gonzalez; Daniel S Fierer; Andrew H Talal
Journal:  Addict Disord Their Treat       Date:  2017-05-17

7.  Position statement on the diagnosis and management of non-alcoholic fatty liver disease.

Authors:  Khalid A Alswat; Hind I Fallatah; Bandar Al-Judaibi; Hussien A Elsiesy; Waleed K Al-Hamoudi; Adel N Qutub; Naif Alturaify; Abdullah Al-Osaimi
Journal:  Saudi Med J       Date:  2019-06       Impact factor: 1.484

8.  Toward precision prescribing for methadone: Determinants of methadone deposition.

Authors:  Andrew H Talal; Yuxin Ding; Charles S Venuto; Lindsay M Chakan; Anthony McLeod; Arpan Dharia; Gene D Morse; Lawrence S Brown; Marianthi Markatou; Evan D Kharasch
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

9.  Role of Magnetic Resonance Imaging in the Monitoring of Patients with Nonalcoholic Fatty Liver Disease: Comparison with Ultrasonography, Lipid Profile, and Body Mass Index.

Authors:  Nikhil Makhija; Naval K Vikram; Gurdeep Kaur; Raju Sharma; Deep N Srivastava; Kumble S Madhusudhan
Journal:  J Clin Exp Hepatol       Date:  2019-09-20

10.  Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography.

Authors:  Maha Abdelmoneim Behairy; Ahmed Fouad Sherief; Hany Aly Hussein
Journal:  Int Urol Nephrol       Date:  2021-03-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.